(Reuters) -Pfizer’s oral COVID-19 therapy will be evaluated as a potential treatment for patients hospitalised with the illness in a major British trial, scientists said on Monday, as cases rise in some parts of the world. The world’s largest randomised study of potential medicines for COVID-19, dubbed the RECOVERY trial, will assess Paxlovid across hospitals in Britain, which has already approved the drug for early-stage treatment. “Paxlovid is a promising oral antiviral drug but we don’t know if it can improve survival of patients with severe COVID-19,” said Peter Horby, a professor at the U…